Oncobiologics Rebrands And Brings In Staff To Push Through Candidate

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

  All change for Oncobiologics as it becomes Outlook Therapeutics, names chief commercial and chief operating officers and collects US$4 million. The New Jersey-based player is solely focused on a novel bevacizumab intravitreal formulation for wet AMD and other retina diseases.

Waves
IT'S A NEW DAWN FOR ONCOBIOLOGICS • Source: Shutterstock

A month after announcing that it had begun dosing patients in its first clinical trial for its lead ONS-5010 novel ophthalmic bevacizumab product candidate for the treatment of wet age-related macular degeneration (wet AMD), Oncobiologics has unveiled several “key corporate events” to bolster efforts to push the drug through the development phase.

With immediate effect, US-based Oncobiologics has changed its corporate identity to Outlook Therapeutics and appointed industry veterans Jeff Evanson as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.